Clinical Trial Update: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS [Phase 1, Phase 2]

View source ↗

Summary

Phase 1-2 study of low-dose ASTX727 in lower-risk myelodysplastic syndromes has completed; the trial was sponsored by Taiho Oncology, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• ASTX727 LD (cedazuridine + decitabine)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED